HPMZ 4-Month Regimen

CDC Interim Guidance

In February 2022, CDC published “Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022.” CDC developed the interim guidance based on evidence from Study 31, sponsored by CDC and conducted by CDC’s Tuberculosis Trials Consortium in collaboration with and the National Institutes of Health (NIH)–sponsored AIDS Clinical Trials Group (ACTG).

NSTC/NTNC Guidance

The National Society of TB Clinicians (NSTC) and National TB Nurse Coalition (NTNC) collaborated to develop A 4-Month Regimen to Treat Pulmonary Tuberculosis: Isoniazid, Rifapentine, Moxifloxacin, and Pyrazinamide (HPMZ). This two-page fact sheet and companion FAQ are intended to give guidance for providers on using the 4-month HMPZ regimen to treat patients for pulmonary TB disease.

The fact sheet includes:

A description of the length, drugs, and dosages of the HPMZ regimen
Photos of medications
Advantages and disadvantages of the HPMZ regimen
Common drug-drug interactions
Possible adverse events
Pre-treatment patient checklist
Baseline and follow-up monitoring and evaluation
Programmatic considerations

For background, more detailed information, and special circumstances, the companion FAQ provides background on Study 31 and answers common questions about medications, monitoring, and special patient populations.

Download your copy here. This resource is provided at no charge, but we do request that you register your download with your email address so that NTCA can track interest in the publication and alert you when updates are released.